Immuneering Co. (NASDAQ:IMRX) Receives Consensus Recommendation of “Buy” from Brokerages

Immuneering Co. (NASDAQ:IMRXGet Rating) has been assigned an average rating of “Buy” from the seven brokerages that are currently covering the firm, reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $29.13.

A number of research firms have recently weighed in on IMRX. Zacks Investment Research raised shares of Immuneering from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research note on Wednesday. Oppenheimer began coverage on shares of Immuneering in a research note on Thursday, March 31st. They issued an “outperform” rating and a $25.00 price target on the stock.

In other news, Director Ann E. Berman purchased 6,000 shares of the firm’s stock in a transaction on Tuesday, March 15th. The stock was bought at an average cost of $6.40 per share, for a total transaction of $38,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have acquired 9,900 shares of company stock valued at $69,201 over the last 90 days.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IMRX. UBS Group AG bought a new stake in shares of Immuneering in the third quarter valued at about $30,000. Citigroup Inc. bought a new stake in shares of Immuneering in the third quarter valued at about $33,000. New York State Common Retirement Fund bought a new stake in shares of Immuneering in the third quarter valued at about $45,000. Metropolitan Life Insurance Co NY bought a new stake in shares of Immuneering in the third quarter valued at about $75,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of Immuneering by 119.5% in the first quarter. JPMorgan Chase & Co. now owns 11,969 shares of the company’s stock valued at $78,000 after buying an additional 6,515 shares during the period. Institutional investors and hedge funds own 47.41% of the company’s stock.

Shares of NASDAQ:IMRX opened at $4.42 on Thursday. Immuneering has a 12-month low of $4.11 and a 12-month high of $33.99. The company’s fifty day moving average is $6.44 and its two-hundred day moving average is $13.79.

Immuneering (NASDAQ:IMRXGet Rating) last posted its quarterly earnings results on Thursday, March 10th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.03). The firm had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.60 million. On average, sell-side analysts forecast that Immuneering will post -2.01 earnings per share for the current fiscal year.

Immuneering Company Profile (Get Rating)

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors.

Read More

Analyst Recommendations for Immuneering (NASDAQ:IMRX)

Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with's FREE daily email newsletter.